Centralized Screening Unit (CSU) at Montefiore-Einstein
- Disease/Condition
- Lung Cancer
- Drug/Device/Intervention
- Centralized Screening Unit Implementation
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- Albert Einstein College of Medicine
- Location
- Bronx, United States of America
- Phase
- N/A
- Start date
- Apr 01, 2024
- End date
- Dec 01, 2028
- Enrollment
- 9460 participants
Participant Referrals,Proportion of participants with early stage lung cancer (LCa)
This study proposes to increase Lung-cancer screening (LCS) in the Bronx, New York. Despite
 strong evidence that Lung-cancer screening (LCS) can reduce Lung cancer (LCa) deaths,
 low-dose computed tomography (LDCT) referral rates by clinicians are very low and there is
 poor adherence with LCS by patients. Both provider and patient barriers may be amenable to
 systemic improvements in support, coordination and infrastructure for screening. The
 investigator team hypothesizes that the implementation of a Central Screening Unit (CSU) that
 shifts routine workflow attributed to LCS (e.g., collection of smoking history, determination
 of eligibility, shared decision making and arranging follow-up) away from busy practices
 (usual care) and that offers patients an array of navigation and support services will
 increase the uptake of LCS guidelines and subsequent low-dose computed tomography (LDCT)
 screening scans in a low-income, predominately Hispanic and Black catchment area. The
 proposed study represents a unique opportunity to test this hypothesis in the context of the
 roll out of a CSU as a significant new component of the Montefiore-Einstein health system.
 The investigator team will examine whether and how the CSU facilitates LCS uptake and
 retention of patients. This study is powered to test whether CSU reduces proportion of
 late-stage lung cancer diagnoses in the Bronx, New York.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06284408
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06284408 through Pure Global AI's free database. This phase not specified trial is sponsored by Albert Einstein College of Medicine and is currently Not yet recruiting. The study focuses on Lung Cancer. Target enrollment is 9460 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.